深圳康泰生物制品股份有限公司 2025 年半年度报告全文 2025 年 08 月 1 深圳康泰生物制品股份有限公司 2025 年半年度报告 深圳康泰生物制品股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人杜伟民、主管会计工作负责人马建英及会计机构负责人(会计 主管人员)黄翠冬声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展规划及经营计划的陈述，不构成公司对投资者 的实质承诺，请投资者注意投资风险。 公司在本报告第三节管理层讨论与分析•十、公司面临的风险和应对措施 章节，披露了公司经营中可能存在的风险及应对措施，敬请投资者关注相关 风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 深圳康泰生物制品股份有限公司 2025 年半年度报告全文 目录 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | ...

| 证券代码：300601 | 证券简称：康泰生物 公告编号：2025-062 | | --- | --- | | 债券代码：123119 | 债券简称：康泰转 2 | 深圳康泰生物制品股份有限公司 第八届董事会第六次会议决议公告 经审核，董事会认为，报告期内公司募集资金的存放、管理与使用情况符合 《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等 法律法规和《公司章程》《募集资金使用管理制度》的相关规定，并及时、真实、 准确、完整地披露了募集资金的存放、管理与使用情况，不存在违规使用募集资 金的行为，也不存在损害公司及股东利益的情况。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳康泰生物制品股份有限公司（以下简称"公司"）第八届董事会第六次 会议通知于 2025 年 8 月 11 日以书面及通讯的方式通知了全体董事，会议于 2025 年 8 月 21 日在公司会议室以现场表决和通讯表决相结合的方式召开。会议召集 人及主持人为公司董事长杜伟民先生，本次会议应参加表决董事 7 人，实际参加 表决董事 7 人。公司监事、高级管理人员 ...

证券之星消息，8月21日生物制品板块较上一交易日上涨0.22%，康泰生物领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。生物制品板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688177 | 百奥泰 | 33.29 | -3.34% | 8.82万 | | 3.03亿 | | 688488 | 文迪药业 | 17.02 | -2.63% | 8.91万 | | ● 1.53亿 | | 000534 | 万泽股份 | 17.20 | -1.99% | 24.29万 | | 4.20亿 | | 300485 | 赛升药业 | 14.19 | -1.80% | - 16.14万 | | 2.31亿 | | 688687 | 凯因科技 | 36.57 | -1.64% | 5.26万 | ...

格隆汇8月21日｜昂利康、九典制药、康泰生物涨超6%，兴齐眼药涨超5%，君实生物、阳光诺和、荣 昌生物涨超3%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 002940 | 昂利康 | 6.59 | 106亿 | 301.09 | | 300705 | 九典制药 | 6.39 | 101亿 | 14.43 | | 300601 | 康泰生物 | 6.14 | 210亿 | 10.48 | | 300573 | 兴齐眼药 | 5.71 | 167亿 | 38.45 | | 600200 | *ST苏吴 | 5.49 | 6.82亿 | -89.70 | | 002424 | 贵州百灵 | 4.79 | 88.75亿 | 64.94 | | 430047 | 诺思兰德 | 3.94 | 80.25亿 | 153.77 | | 300147 | ST香雪 | 3.81 | 75.65亿 | 17.09 | | 688180 | 君实生物-し | 3.44 | 476亿 | 69.67 | | 688621 | 阳光诺 ...

从资金流向上来看，当日生物制品板块主力资金净流出8.57亿元，游资资金净流入2.95亿元，散户资金净 流入5.62亿元。生物制品板块个股资金流向见下表： 证券之星消息，8月20日生物制品板块较上一交易日下跌0.42%，荣昌生物领跌。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688319 | 欧林生物 | 33.11 | 6.09% | 17.16万 | 5.59亿 | | 000534 | 万泽股份 | 17.55 | 4.84% | 34.99万 | 6.03亿 | | 000518 | *ST四环 | 2.30 | 2.68% | 18.92万 | 4320.70万 | | 300601 | 康泰生物 | 17.74 | 2.54% | 1 36.24万 | 6.38亿 | | 688443 | 智翔全泰 | 33.61 | 1.69% | 5.48万 | ...

Group 1 - The overall number of vaccine batch approvals in the first half of 2025 is 1,629, representing a year-on-year decrease of 17% [1] - Certain vaccines, such as rabies and HPV vaccines, have seen significant growth in batch approvals, while others like polio, meningitis, and measles-mumps-rubella vaccines have experienced substantial declines [1] - Several key vaccines have received approval for market launch in the first half of the year, including CanSino's PCV13 and Wantai's 9-valent HPV vaccine [1] Group 2 - Multiple products are currently in the review stage for market approval, including Zhifei's PCV15 and MCV4, as well as Kangtai's IPV and quadrivalent influenza vaccines [1] - It is anticipated that sales of certain products in the second half of 2025 may improve year-on-year, driven by new product launches contributing to revenue growth [1] - The ongoing development of innovative vaccine pipelines and expectations for external licensing are areas of interest, along with the implications of recent equity changes in some companies and the potential impact of new shareholders [1]

Core Viewpoint - Kangtai Biological (300601) has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine, indicating a significant advancement in its product pipeline [1] Company Summary - The trivalent influenza virus split vaccine is developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [1] - The vaccine is intended for individuals aged 3 years and older, aiming to stimulate the immune system to produce antibodies against influenza viruses [1] Industry Summary - The approval for clinical trials reflects ongoing efforts in the biopharmaceutical industry to enhance vaccine development, particularly in response to seasonal influenza outbreaks [1]

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has received approval for clinical trials of its trivalent influenza virus split vaccine, indicating progress in its vaccine development efforts [2]. Group 1 - The trivalent influenza virus split vaccine (MDCK cell) was developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [2] - The approval was granted by the National Medical Products Administration, confirming that the vaccine meets the necessary requirements for drug registration [2]. - The clinical trial approval is in accordance with the Pharmaceutical Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China [2].

Core Viewpoint - Kangtai Biological (300601.SZ) has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (MDCK cell) for clinical trials, marking a significant step in its vaccine development efforts [1] Company Summary - The trivalent influenza virus split vaccine is designed for individuals aged 3 years and older, aiming to stimulate the immune system to produce antibodies against influenza viruses [1] - This vaccine is intended for the prevention of influenza caused by vaccine-related strains of the virus [1] - Currently, there are no approved trivalent influenza virus split vaccines (MDCK cell) available in the domestic market [1] Industry Summary - The approval of this vaccine follows the precedent set by international manufacturers such as Seqirus, which have successfully launched MDCK cell-based influenza vaccines [1] - The development of this vaccine could enhance the competitive landscape of influenza prevention in the domestic market [1]

Core Viewpoint - Kangtai Biological (300601.SZ) has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine (MDCK cells) [1] Company Summary - The trivalent influenza virus split vaccine is developed in collaboration with Lanzhou Bailing Biotechnology Co., Ltd. [1] - The vaccine is intended for individuals aged 3 years and older, aiming to stimulate the immune response against influenza viruses [1] Industry Summary - The approval aligns with the requirements set forth by the Drug Administration Law and Vaccine Administration Law of the People's Republic of China [1] - The vaccine is designed to prevent influenza caused by vaccine-related virus strains, addressing public health needs [1]